The aim of this investigation was to develop a fast and convenient method for the determination of (-)-linalool in human whole blood to facilitate pharmacokinetic studies. Analytical protocols were elaborated for three different GC/MS sampling techniques, i.e., static headspace (s-HS), headspace solid phase micro extraction (HS-SPME), and liquid-liquid partition. In principle, all tested methods were feasible, but s-HS had the greatest benefit because of the easy handling of the blood samples and its short analysis time. For s-HS two different incubation temperatures were tested (40°C and 60°C). The limit of detection was slightly lower when samples were incubated at 60°C, but the same quantitative results were achieved using α-terpineol as internal standard. An accurate and sensitive method for the quantification of (-)-linalool in blood samples after either inhalation or percutaneous application, as well as pharmacokinetic data are presented.
Essential oils are often used in traditional medicine. For instance, in aromatherapy, Eucalyptus essential oil is well known to be activating, whereas Lavender essential oil is deemed sedative. Nevertheless, our knowledge of these substances and their influence on the human organism is still very limited. Several studies have reported on the pharmacological, physiological and psychopharmacological effects of monoterpenes and showed that the mode of administration has a significant influence on their outcome [1a-1c] . For instance, in one study [1a] , 1,8-cineol improved attentional performance and increased respiration rate in comparison with (±)linalool after dermal application,but not after inhalation.
To date, a number of investigations have used different techniques to quantify volatile compounds in several biological matrices, such as blood, plasma and urine. In a study of Fewell et al. [1d] , headspace solid phase micro extraction (HS-SPME) was shown to be appropriate for the quantitative analysis of the monoterpene d-limonene in biological samples. Using HS-SPME, the volatile analytes are partitioned between the matrix and the so-called headspace, i.e., the gasphase above the matrix, in a closed system and can be adsorbed onto a special fiber. During conventional aromatherapy, massage with a 4% solution of a sweet orange oil diluted in fractionated coconut oil resulted in an average concentration of 12 ng • mL -1 of d-limonene in human blood [1d] . Automated HS-SPME was also used in a study for the determination of thymol in human plasma [2a] . However, after an oral dose of 1.08 mg, no free thymol could be detected in human plasma [2b] . Another technique for the quantification of volatile compounds in various matrices, for example blood, is static headspace (s-HS) analysis. Analytes dissolved in blood are partitioned between the blood and the headspace in a closed system and the concentration of the analytes in the headspace is determined, which is proportional to the concentration of the analytes in the blood [2c] . Using this method, Dills et al. were able to analyze several volatile solvents with a limit of quantification (LOQ) of 0.01 µg • mL -1 [2d].
A third method for the analysis of volatile compounds in biological fluids is liquid injection after adequate preparation of the biological samples. For this purpose, purification of the samples with analytical columns is necessary. A common technique for sample preparation used in this context is solid phase extraction (SPE). Jäger et al. used SPE followed by liquid injection to quantify the monoterpene (±)-carvone and its metabolites in human plasma and urine [3a] , as well as linalool and linalyl acetate from human plasma [3b]. An alternative is liquid-liquid partition using pre-packed columns for liquid-liquid extraction of lipophilic compounds from aqueous solutions. The blood is adsorbed onto the sorbent material and the lipophilic compounds can be extracted by eluting the cartridge with a non polar solvent.
The main goal of this study was to develop a convenient and efficient analytical procedure for the quantification of (-)-linalool in human whole blood that was appropriate for the automated analysis of large numbers of blood samples in the context of pharmacokinetic studies.
The s-HS method turned out to be the fastest and most convenient. Sensitivity of s-HS was examined with heparinised human blood samples from six different sources obtained from the Austrian Red Cross, as well as with blood samples of volunteers. The blank blood showed no interfering peaks at the retention times of (-)-linalool and α-terpineol when using mass spectrometry in SIM mode. Some of the blood samples showed a small peak at the retention time of α-terpineol, which was well below LOQ. Nevertheless, the area of this peak was subtracted from the area of the α-terpineol peak prior to analysis. Figure 1 shows a chromatogram of a blood sample from one volunteer 45 min after dermal application of (-)-linalool. For the 40°C incubation method, LOQ was determined at 0.05 µM • mL -1 according to 7.69 ng • mL -1 (S/N = 10:1). In the case of 60°C incubation, LOQ was found at 0.025 µM • mL -1 or 3.85 ng • mL -1 (S/N = 10:1). The limit of detection (LOD) was calculated as 0.0025 µM• mL -1 or 0.38 ng • mL -1 (S/N = 3:1) at 40°C incubation, and as 0.001 µM • mL -1 or 0.15 ng • mL -1 (S/N 3:1) at 60°C. For HS-SPME, LOQ was determined at 0.025 µM • mL -1 according to 3.85 ng • mL -1 (S/N = 10:1) and LOD at 0.001 µM • mL -1 or 0.154 ng • mL -1 (S/N = 3:1). For liquid-liquid partition, however, LOQ was determined at 0.1 µM • mL -1 according to 15.4 ng • mL -1 (S/N = 10:1) and LOD at 0.005 µM • mL -1 or 0.77 ng • mL -1 (S/N = 3:1).
For all methods, linearity studies were conducted with eight standard solutions of (-)-linalool, which were added to heparinised blood samples to yield the following concentrations: 0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 0.75 and 1 µM • mL -1 equivalent to 3. 85, 7.69, 15.38, 38.45, 76.9, 115.35 and 153 .8 ng • mL -1 , respectively.
For s-HS, calibration curves were determined three times (40°C method) and twice (60°C method), respectively. The standard curves were linear from 0.05 µM • mL -1 (7.69 ng • mL -1 ) to 1 µM • mL -1 (153.8 ng • mL -1 ) for 40°C incubation, with correlation coefficients in the range of R 2 = 0.993-0.997. In the case of the 60°C method, linearity ranged from 0.025 µM • mL -1 (3.85 ng • mL -1 ) to 1 µM • mL -1 (153.8 ng • mL -1 ) with correlation coefficients in the range of R 2 = 0.994-0.999 (Table 1) . For HS-SPME, as well as liquid-liquid partition, calibration curves were calculated twice. The standard curves for HS-SPME were linear from 0.025 µM • mL -1 (3.85 ng • mL -1 ) to 1 µM • mL -1 (153.8 ng • mL -1 ) with correlation coefficients in the range of R 2 = 0.983-0.999 (Table 2 ). In the case of liquid-liquid partition, linearity ranged from 0.1 µM • mL -1 (15.4 ng • mL -1 ) to 1 µM • mL -1 (153.8 ng • mL -1 ) with correlation coefficients in the range of R 2 = 0.992-0.998 (Table 3) .
From literature reports we know that HS-SPME, s-HS and SPE followed by liquid injection are appropriate for quantification of volatile compounds from biological matrices [1d-2c,3a,3b] . In our study, s-HS proved best suited for such analyses because of easy sample preparation and a short analysis time. HS-SPME was also characterized by easy sample preparation. Although LOD and LOQ at an incubation temperature of 40°C were lower than for s-HS, HS-SPME had a great disadvantage concerning analysis time. In s-HS mode, six samples could be incubated in the TriPlus TM autosampler simultaneously, whereas the HS-SPME mode allowed for the incubation of only one sample at a time. In addition, after each injection, the fiber had to be desorbed at 250°C for 30 min at the fiber conditioning port to avoid carryover of analytes to the next sample. This led to a long analysis time of about 90 min per sample. For our series of eight samples per subject this added up to a total analysis time of 12 h per subject. In contrast, with s-HS only 2 h per subject were needed. Liquid-liquid partition followed by liquid injection was associated with complex and time consuming steps of sample preparation. In our study, liquid-liquid partition was carried out over crushed ice at an ambient temperature of 4°C. Nevertheless, the loss of analytes was greater than 50%. Thus, in our opinion, this method is inappropriate for the analysis of volatile compounds such as monoterpenes.
S-HS met all our demands with regard to convenience and efficiency. Therefore, precision and accuracy were only determined for this method. Intra-day precision at each incubation temperature was determined at three concentrations by running three replicates and was expressed as the relative standard deviation (%RSD) of the peak area ratios. Accuracy was determined in the same way by the relative error (%RE). Inter-day precision calculations were determined on three (40°C incubation temperature) and two days (60°C incubation temperature), respectively (Tables 4-7) .
For the determination of the response factor (f St ), 4 mL of blank blood was spiked with 0.5 µM • mL -1 α-terpineol (internal standard) and adequate amounts of (-)-linalool were added. The factor was calculated by means of the formula shown below, in which f St is the response factor, STD is the standard, and ISTD the internal standard:
S-HS is an accurate and useful method for the quantification of solvents in blood [2d]. For s-HS incubation, two different temperatures were tested. First, the samples were incubated at 40°C because this was the lowest temperature available for the instrumental setup. Second, an incubation temperature of 60°C was tested to increase headspace sensitivity [3c] . We found that increasing the incubation temperature led to a decrease of the LOQ, but had no effect on quantity. Dills et al. [2d] also found a maximum response at an incubation temperature of 60°C. At higher temperatures, blood coagulated prior to sampling. In their study, the partitioning of an analyte from a solid (coagulated blood) to the headspace was less efficient than from a liquid to the headspace.
In order to decrease LOQ we tested different sample volumes, i.e., 3, 4 and 5 mL, as well as salting-out with ammonium sulfate and sodium chloride. A sample volume of 4 mL yielded the best results in terms of LOQ. Salting out is sometimes used to increase the amount of an analyte [3c], but in our case, however, it led to an interfering peak at the retention time of (-)-linalool. These findings resembled those of Dills et al. who found a decrease in the sensitivity after salting-out because of the coagulative effects of the salts on blood [2d]. In our study, we determined a mean LOQ for (-)-linalool of 7.7 ng • mL -1 and 3.8 ng • mL -1 at incubation temperatures of 40°C and 60°C, respectively. These findings are similar to those reported by other authors [1d,2a] . ) , Solution (% ,w/w; g): concentration (% ,w/w)) and amount (in g) of the applied (-)-linalool solution; IT: incubation temperature (°C), -: amount below LOQ. Our preliminary pharmacokinetic data (Tables 8 and 9 ) showed considerable differences in (-)-linalool content in human blood, mostly due to great inter-individual variability. Moreover, sex differences were observed, particularly after dermal application. After inhalation, a maximum of 12.6 ng • mL -1 of (-)-linalool was found, whereas after dermal application a maximum of 72.7 ng • mL -1 was detected. After inhalation, similar amounts of (-)-linalool were detected in males and females. In contrast, after dermal administration it seems that male subjects showed a better up-take than female subjects Visual inspection suggested a correlation of these results to individual body fat ratios, which differed significantly as a function of sex (Mann-Whitney U = 0.000, P = 0.001). Statistical analysis showed no significant association between the mean blood levels of (-)-linalool and individual body fat ratios in the inhalation condition (Spearman ρ = 0.107, P > 0.1), but a strong trend toward significance in the dermal application condition (Spearman ρ = -0.567, P = 0.056).
In terms of the time course of the absorption of (-)-linalool, we expected an earlier onset in the inhalative condition since lipophilic monoterpenoids are likely to accumulate in subcutaneous fatty tissue when administered to the skin [1d]. Indeed, when (-)-linalool was inhaled, it appeared at about 25 min in most of our subjects and blood levels decreased again after 40 to 45 min in some subjects. In contrast, after dermal application, blood levels above LOQ were detected slightly later, i.e., after 30 min. On the other hand, in some subjects, blood levels of (-)-linalool did not exceed LOQ until after 35 and even 40 min of exposure, irrespective of the way of administration. While no pharmacokinetic data are available for (-)-linalool after inhalation in humans, Jäger et al. [3b] detected the substance already at about 5 min after massage of the essential oil of Lavender. This is clearly earlier than in our study. However, these incoherent results may be explained by differences in the experimental setup [4a] , such as a larger area of exposure and a 5-fold massage time in the study by Jäger et al. [3b] , or by differences in the body composition of their subject. Thus, further investigations with more individuals are needed to study the exact time course of the absorption of (-)-linalool and to confirm our hypothesis of a relationship between uptake rate and body fat ratio.
In an investigation of the effect of (-)-linalool on the human central nervous system we found that brain activation in a vigilance task by (-)-linalool was dependent on the mode of application and that dermal administration generated greater significant activation of brain regions than inhalation. In addition, significant sex differences in brain activation were observed in the dermal condition, i.e., male subjects responded with more and stronger activation of brain areas to the transdermal administration of (-)-linalool than females [4b] . Although preliminary, our pharmacokinetic data correspond well with these findings and could thus provide a pharmacological basis for the sedative effects of (-)-linalool reported in earlier studies of our group [1a,1b] .
Experimental

Chemicals and materials:
The monoterpenoids (-)-linalool (>95%, CAS 78-70-6) and α-terpineol (>98%, CAS 8000-41-7), as well as n-hexane for GC (>99.0%, CAS 111-27-3) were purchased from Sigma Aldrich, Germany. Peanut oil (CAS 8002-03-7) and propylene glycol (CAS 57-55-6) were pharmaceutical grade (Ph. Eur.). Compressed air for respiration purposes was purchased from Air Liquide, Austria. The breathing mask system "ANZAI" was obtained from B+P Beatmungsprodukte GmbH, Germany, and was coupled with an Inhalette ® system from Dräger, Austria. Blood samples were drawn into 9 mL Lithium Heparin Vacuette ® containers by way of a Vacuette Holdex ® single use holder (Greiner Bio-One, Austria) and a permanent venous catheter (DB Venflon ™ 20GA, 1.0 x 32 mm, DB Medical, NJ, USA). The catheter was fixed with Applica i.v. 100, 8 x 6 cm (Smith & Nephew, United Kingdom) and rinsed with 0.9 % saline solution "Fresenius" (Kabi, Austria). Collected blood samples were immediately closed airtight with Parafilm ® M (Sigma Aldrich). Extrelut ® NT3 analytical cartridges (Merck, Germany) were used for purification of the blood samples. The body fat ratio of each subject was determined with the Body Fat Monitor BF306 (Omron Medizintechnik, Germany).
For s-HS and HS-SPME, 20 mL headspace crimp top vials combined with Al Crimp Cap & Seal caps (Thermo Scientific, Austria), and for liquid injection 2 mL screw vials (Thermo Scientific) were used. For HS-SPME a 100 µm polydimethyl siloxane SPME fiber (Supelco) was used. S-HS injection was performed with a 2.5 mL Hamiliton HT gastight syringe (Thermo Scientific).
Apparatus:
Gas chromatography was performed on a Thermo Scientific GC system with a split-split less injector port, equipped with a TR1-MS capillary column (30 m x 0.25 mm x 0.25µm; Thermo Scientific), and combined with a DSQII mass spectrometer, and a TriPlus TM autosampler (Thermo Scientific), which was coupled with a fiber conditioning port and an agitator for incubation. Data analysis was performed with Xcalibur TM software 1.4. SR1, © Thermo Electron Corporation 1998-2003.
Sample preparation:
All sample preparation was carried out at 4°C. Four mL of heparinised blood obtained from the Austrian Red Cross was spiked with 4 µL of the appropriate concentration (see above) of (-) -linalool and with 4 µL of 0.5 µM/mL -1 α-terpineol as the internal standard. These samples were then vortexed for 1 min at 600 rpm. Before liquid injection the samples were purified by means of liquid-liquid partition. Three mL of each blood sample was transferred to Extrelut ® NT3 analytical cartridges, eluted with 15 mL high purity n-hexane and the solvent was removed under reduced pressure. The residue was redissolved in 500 µL n-hexane and 1 µL thereof was applied for analysis.
GC/MS conditions:
Chromatography for all methods was carried out in split-split less mode (sampling time 1 min., split ratio 1:10) with an injector temperature of 220°C. Oven temperature was set at 40°C for 1 min and increased to 160°C at 20°C/min. The mass spectrometer operated in selected ion monitoring (SIM) mode using m/z 71 and m/z 93 for (-)-linalool and m/z 59 and m/z 93 for α-terpineol (dwell time 60 ms each). Ion source was set at 200°C and MS transfer line at 180°C.Helium 5.0 was used as carrier gas at a constant flow rate of 1.5 mL/min for HS-SPME and liquid-liquid partition. For s-HS a programmed flow rate was used. After an initial flow of 3 mL/min for 1 min the flow was decreased to 1.5 mL/min for the remaining time of the analysis.
Using HS-SPME, incubation was carried out for 20 min at 40°C, and headspace volatiles were adsorbed onto the SPME fiber for 40 min. The desorption time was set at 2 min. After each injection the fiber was desorbed at 250°C for 30 min at the fiber conditioning port to avoid carry over of analytes to the following sample. During incubation, agitation was on for 10 s and off for 50 s.
Using s-HS mode, the syringe temperature was set at 50°C when the incubation temperature was 40°C and at 80°C when incubation was carried out at 60°C. Separate tests showed that equilibrium conditions were reached after 30 min of incubation at both 40°C and 60°C. During incubation, agitation was on for 10 s and off for 10 s.
Pharmacokinetic studies:
The study was reviewed and approved by the Institutional Review Board of the Medical University and the General Hospital of Vienna. Twenty-five subjects took part in the study who were randomly divided into 2 groups, i.e., an inhalative group and a dermal group. The samples of 4 individuals were excluded, in 3 cases because of an error in sample preparation and in 1 case due to incorrect GC conditions. Thus, the dermal group consisted of 14 subjects (7 males). In 3 females in this condition, blood levels of (-)-linalool were below LOQ and no data are shown for these subjects in Table 8 . In the inhalative condition 7 volunteers (3 males) were studied. All subjects were recruited by announcement on an internet based students job exchange. All participants were healthy, normal-weighted, non smokers between 19 and 40 years. Only hormonal contraception was allowed for the women taking part. In addition, volunteers were not allowed to take any medication, had no allergies, asthma or other respiratory diseases. Furthermore, they refrained from using various cosmetic products, such as shower gel, shampoo and lotions, for 2 days, as well as from drinking coffee, tea and energy drinks for 24 h before the study. Also, they were neither allowed to donate blood nor to take part in other clinical experiments for 3 weeks before and after the study. Qualification for participation was checked before study. In addition, blood pressure, heart rate, body mass index, weight, height, abdominal girth, hip size and body fat ratio were collected. All volunteers gave written informed consent prior to participation in the study and were free to withdraw at any time.
In the dermal condition, the volunteers received odorless air via a breathing mask during the whole period of blood collection. Each subject received a solution of (-)-linalool in peanut oil on a defined skin area (10 x 20 cm) of the lower abdomen. Details of the administration regime are given in Table 8 . The solution was massaged into the skin for 2 min and then covered with a thermoplastic foil to avoid evaporation. In addition, the volunteers obtained a blanket in order to (i) reproduce the situation in a magnetic resonance scanner and (ii) to enhance absorption into the blood. In the inhalative condition, the volunteers received odorless air during drawing of the blank blood sample. Thereafter, the Inhalette® coupled to the breathing mask was changed and the subjects were breathing a 10%, w/w, solution of (-)-linalool in propylene glycol during the rest of the session.
Eight 9 mL blood samples were drawn from the right cubital vein over a maximum of 45 min. Time points of blood draws in each individual are given in Tables 6  and 7 . [In 2 subjects (1 male) in the inhalative group, blood was also drawn at 5 and 10 min, but these time points were abandoned since (-)-linalool levels did not reach LOQ.] Blood samples were drawn into Vacuette ® containers. Each blood sample was immediately wrapped airtight with Parafilm ® M, cooled in crushed ice and stored at 4°C before preparation for the analysis, which was carried out within one h after the beginning of the study. After each blood sample had been taken, the catheter was rinsed with 0.9% saline solution to avoid agglutination of blood. In order to provide accurate sample collection, the first 2 mL of the following sample were rejected.
